サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：経口抗ウイルス薬の世界市場：適応症別（肝炎、ヒト免疫不全ウイルス、インフルエンザ、その他）、薬剤クラス別、流通チャネル別：機会分析と産業予測、2021-2031年
市場調査レポート
商品コード
1266405

経口抗ウイルス薬の世界市場：適応症別（肝炎、ヒト免疫不全ウイルス、インフルエンザ、その他）、薬剤クラス別、流通チャネル別：機会分析と産業予測、2021-2031年

Oral Antiviral Market By Indication (Hepatitis, Human Immunodeficiency Virus, Influenza, Others), By Drug class, By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日: | 発行: Allied Market Research | ページ情報: 英文 385 Pages | 納期: 2～3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
経口抗ウイルス薬の世界市場：適応症別（肝炎、ヒト免疫不全ウイルス、インフルエンザ、その他）、薬剤クラス別、流通チャネル別：機会分析と産業予測、2021-2031年
出版日: 2023年02月01日
発行: Allied Market Research
ページ情報: 英文 385 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

経口抗ウイルス薬市場規模は、2021年に352億1,348万米ドルと評価され、2022年から2031年にかけて2.1%のCAGRを示し、2031年には433億9,400万米ドルに達すると予測されています。

抗ウイルス薬は、特にウイルス感染症の治療に使用される医薬品の一種です。特定の抗ウイルス剤は、特定のタイプのウイルスの治療に使用されます。経口抗ウイルス剤は、ウイルス感染症を治療するために口から服用する薬です。また、抗ウイルス剤は、一般的な抗生物質とは異なり、標的となる病原体を破壊するのではなく、むしろその発育を阻害するものです。さらに、これらの薬剤は、ウイルスのライフサイクルの様々な段階、例えば、複製や組み立てを阻害することにより、症状の重症度や持続時間を減少させ、また、他の人へのウイルスの拡散を減少させます。さらに、インフルエンザに対するバロキサビルマルボキシル＆ザナミビル、肝炎に対するレディパスビル＆ソホスブビル、ヒト免疫不全ウイルス（HIV）に対するダルナビル＆ラミブジンなど、多くの経口抗ウイルス薬がウイルス感染の治療に承認・利用されています。

経口抗ウイルス剤市場の促進要因は、インフルエンザ、ヒト免疫不全ウイルス（HIV）、肝炎などのウイルス感染症の流行が増加していることです。例えば、米国疾病管理予防センター（CDC）2022年の報告によると、インフルエンザの症例は900万件で、400万件の受診と1万件の入院が報告されています。したがって、インフルエンザの有病率の上昇は、市場の成長を促進することが期待されます。また、全世界で肝炎やヘルペスの有病率が上昇していることも、市場の成長を促進すると予想されます。さらに、ウイルス感染症治療薬のパイプラインが増加し、今後数年間で規制当局の承認を受けることが予想されるため、市場の成長を促進します。

さらに、さまざまなプログラムやキャンペーンを通じて、ウイルス性疾患や利用可能な経口治療薬に関する患者の認識を高めるための非政府組織や政府組織による取り組みが増加し、市場の成長を後押しすると予測されています。また、ウイルス性疾患の診断に高度な技術を採用する動きが活発化し、肝炎やヒト免疫不全ウイルス（HIV）などのウイルス性感染症の早期診断の重要性が認識されるようになったことも、市場の成長を後押しすると予測されています。さらに、多くの主要企業が、世界の経口抗ウイルス剤市場における存在感を高めるために、提携、合意、アライアンスなどの主要戦略を採用しており、これが市場の成長を促進すると予想されます。

しかし、経口抗ウイルス薬のコストが高いなどの要因が、経口抗ウイルス薬市場の成長を抑制する可能性があります。また、インフルエンザ、肝炎、ヒトパピローマウイルス（HPV）、ヘルペスなどのウイルス性疾患に対するワクチンの入手可能性が、市場の成長を阻害すると予想されます。さらに、ウイルス感染症を治療するための新規治療薬の需要の増加や、抗ウイルス薬の規制当局による承認の増加は、市場の主要プレーヤーに有利な機会を提供すると期待されています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • トップインパクトファクター
    • トップインベストメントポケット
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 買い手の交渉力
    • 代替品の脅威
    • 新規参入業者の脅威
    • ライバルの強さ
  • 市場力学
    • 促進要因
      • ウイルス感染症の増加
      • ウイルス感染症に関する政府の取り組みが活発化
      • 抗ウイルス剤の承認取得の増加
    • 抑制要因
      • HIV治療薬の承認と商業化に関する厳しい規制要件
    • 機会
      • 新興国における成長機会
  • COVID-19市場への影響度分析

第4章 経口抗ウイルス薬市場：適応症別

  • 概要
    • 市場規模・予測
  • 肝炎
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • ヒト免疫不全ウイルス（HIV）
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • インフルエンザ
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • その他
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第5章 経口抗ウイルス薬市場：薬効分類別

  • 概要
    • 市場規模・予測
  • プロテアーゼ阻害剤
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • 逆転写酵素阻害剤
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • その他
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第6章 経口抗ウイルス薬市場：流通チャネル別

  • 概要
    • 市場規模・予測
  • 病院内薬局
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • ドラッグストア・小売薬局
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析
  • オンラインプロバイダー
    • 主な市場動向、成長要因、機会について
    • 市場規模・予測：地域別
    • 市場シェア分析：国別分析

第7章 経口抗ウイルス薬市場：地域別

  • 概要
    • 市場規模・予測：地域別
  • 北米
    • 主な動向と機会
    • 市場規模・予測：適応症別
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 米国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • カナダ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • メキシコ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
  • 欧州
    • 主な動向と機会
    • 市場規模・予測：適応症別
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ドイツ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • フランス
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • 英国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • イタリア
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • スペイン
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • その他欧州
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
  • アジア太平洋地域
    • 主な動向と機会
    • 市場規模・予測：適応症別
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • 日本
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • 中国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • インド
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • オーストラリア
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • 韓国
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • その他アジア太平洋地域
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
  • LAMEA
    • 主な動向と機会
    • 市場規模・予測：適応症別
    • 市場規模・予測：薬物クラス別
    • 市場規模・予測：流通チャネル別
    • 市場規模・予測：国別
      • ブラジル
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • サウジアラビア
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • 南アフリカ
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別
      • LAMEAの残りの地域
      • 主な市場動向、成長要因、機会について
      • 市場規模・予測：適応症別
      • 市場規模・予測：薬物クラス別
      • 市場規模・予測：流通チャネル別

第8章 競合情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合ヒートマップ
  • トップ企業のポジショニング、2021年

第9章 企業プロファイル

  • Gilead Sciences, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Amneal Pharmaceuticals LLC
図表

LIST OF TABLES

  • TABLE 01. GLOBAL ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 02. ORAL ANTIVIRAL MARKET FOR HEPATITIS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 03. ORAL ANTIVIRAL MARKET FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY REGION, 2021-2031 ($MILLION)
  • TABLE 04. ORAL ANTIVIRAL MARKET FOR INFLUENZA, BY REGION, 2021-2031 ($MILLION)
  • TABLE 05. ORAL ANTIVIRAL MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 06. GLOBAL ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 07. ORAL ANTIVIRAL MARKET FOR PROTEASE INHIBITORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 08. ORAL ANTIVIRAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 09. ORAL ANTIVIRAL MARKET FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. GLOBAL ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 11. ORAL ANTIVIRAL MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 12. ORAL ANTIVIRAL MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. ORAL ANTIVIRAL MARKET FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 14. ORAL ANTIVIRAL MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. NORTH AMERICA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 16. NORTH AMERICA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 17. NORTH AMERICA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 18. NORTH AMERICA ORAL ANTIVIRAL MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. U.S. ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 20. U.S. ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 21. U.S. ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 22. CANADA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 23. CANADA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 24. CANADA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 25. MEXICO ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 26. MEXICO ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 27. MEXICO ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 28. EUROPE ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 29. EUROPE ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 30. EUROPE ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 31. EUROPE ORAL ANTIVIRAL MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 32. GERMANY ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 33. GERMANY ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 34. GERMANY ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 35. FRANCE ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 36. FRANCE ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 37. FRANCE ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 38. UK ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 39. UK ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 40. UK ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 41. ITALY ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 42. ITALY ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 43. ITALY ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 44. SPAIN ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 45. SPAIN ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 46. SPAIN ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 47. REST OF EUROPE ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 48. REST OF EUROPE ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 49. REST OF EUROPE ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 50. ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 51. ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 52. ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 53. ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 54. JAPAN ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 55. JAPAN ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 56. JAPAN ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 57. CHINA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 58. CHINA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 59. CHINA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 60. INDIA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 61. INDIA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 62. INDIA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 63. AUSTRALIA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 64. AUSTRALIA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 65. AUSTRALIA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 66. SOUTH KOREA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 67. SOUTH KOREA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 68. SOUTH KOREA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 72. LAMEA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 73. LAMEA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 74. LAMEA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 75. LAMEA ORAL ANTIVIRAL MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 76. BRAZIL ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 77. BRAZIL ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 78. BRAZIL ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 79. SAUDI ARABIA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 80. SAUDI ARABIA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 81. SAUDI ARABIA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 82. SOUTH AFRICA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 83. SOUTH AFRICA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 84. SOUTH AFRICA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 85. REST OF LAMEA ORAL ANTIVIRAL MARKET, BY INDICATION, 2021-2031 ($MILLION)
  • TABLE 86. REST OF LAMEA ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021-2031 ($MILLION)
  • TABLE 87. REST OF LAMEA ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 88. GILEAD SCIENCES, INC.: KEY EXECUTIVES
  • TABLE 89. GILEAD SCIENCES, INC.: COMPANY SNAPSHOT
  • TABLE 90. GILEAD SCIENCES, INC.: PRODUCT SEGMENTS
  • TABLE 91. GILEAD SCIENCES, INC.: PRODUCT PORTFOLIO
  • TABLE 92. GILEAD SCIENCES, INC.: KEY STRATERGIES
  • TABLE 93. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 94. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 95. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 96. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 97. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 98. MERCK & CO., INC.: KEY EXECUTIVES
  • TABLE 99. MERCK & CO., INC.: COMPANY SNAPSHOT
  • TABLE 100. MERCK & CO., INC.: PRODUCT SEGMENTS
  • TABLE 101. MERCK & CO., INC.: PRODUCT PORTFOLIO
  • TABLE 102. ABBVIE INC.: KEY EXECUTIVES
  • TABLE 103. ABBVIE INC.: COMPANY SNAPSHOT
  • TABLE 104. ABBVIE INC.: PRODUCT SEGMENTS
  • TABLE 105. ABBVIE INC.: PRODUCT PORTFOLIO
  • TABLE 106. ABBVIE INC.: KEY STRATERGIES
  • TABLE 107. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
  • TABLE 108. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 109. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
  • TABLE 110. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 111. GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 112. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 113. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 114. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 115. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 116. JOHNSON & JOHNSON: KEY EXECUTIVES
  • TABLE 117. JOHNSON & JOHNSON: COMPANY SNAPSHOT
  • TABLE 118. JOHNSON & JOHNSON: PRODUCT SEGMENTS
  • TABLE 119. JOHNSON & JOHNSON: PRODUCT PORTFOLIO
  • TABLE 120. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 121. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 122. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 123. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 124. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 125. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 126. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 127. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 128. AMNEAL PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 129. AMNEAL PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 130. AMNEAL PHARMACEUTICALS LLC: PRODUCT SEGMENTS
  • TABLE 131. AMNEAL PHARMACEUTICALS LLC: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. ORAL ANTIVIRAL MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF ORAL ANTIVIRAL MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN ORAL ANTIVIRAL MARKET (2022-2031)
  • FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW BARGAINING POWER OF BUYERS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. LOW THREAT OF NEW ENTRANTS
  • FIGURE 08. LOW INTENSITY OF RIVALRY
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALORAL ANTIVIRAL MARKET
  • FIGURE 10. ORAL ANTIVIRAL MARKET, BY INDICATION, 2021(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR HEPATITIS, BY COUNTRY 2021-2031(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR HUMAN IMMUNODEFICIENCY VIRUS (HIV), BY COUNTRY 2021-2031(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR INFLUENZA, BY COUNTRY 2021-2031(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 15. ORAL ANTIVIRAL MARKET, BY DRUG CLASS, 2021(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR PROTEASE INHIBITORS, BY COUNTRY 2021-2031(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR OTHERS, BY COUNTRY 2021-2031(%)
  • FIGURE 19. ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL, 2021(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR DRUG STORE AND RETAIL PHARMACIES, BY COUNTRY 2021-2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF ORAL ANTIVIRAL MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2021-2031(%)
  • FIGURE 23. ORAL ANTIVIRAL MARKET BY REGION, 2021
  • FIGURE 24. U.S. ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 25. CANADA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 26. MEXICO ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 27. GERMANY ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 28. FRANCE ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 29. UK ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 30. ITALY ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 31. SPAIN ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 32. REST OF EUROPE ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. JAPAN ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. CHINA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. INDIA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. AUSTRALIA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. SOUTH KOREA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. BRAZIL ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. SAUDI ARABIA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. SOUTH AFRICA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. REST OF LAMEA ORAL ANTIVIRAL MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47. COMPETITIVE DASHBOARD
  • FIGURE 48. COMPETITIVE HEATMAP: ORAL ANTIVIRAL MARKET
  • FIGURE 49. TOP PLAYER POSITIONING, 2021
  • FIGURE 50. GILEAD SCIENCES, INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 51. F. HOFFMANN-LA ROCHE LTD.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 52. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 54. MERCK & CO., INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 55. MERCK & CO., INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 56. MERCK & CO., INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 57. ABBVIE INC.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 58. ABBVIE INC.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 59. ABBVIE INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 60. GLAXOSMITHKLINE PLC: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 61. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 62. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 63. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2019-2021 ($MILLION)
  • FIGURE 64. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 65. JOHNSON & JOHNSON: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 66. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 67. JOHNSON & JOHNSON: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 68. TEVA PHARMACEUTICAL INDUSTRIES LTD.: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 69. TEVA PHARMACEUTICAL INDUSTRIES LTD.: REVENUE SHARE BY SEGMENT, 2021 (%)
  • FIGURE 70. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 71. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 72. AMNEAL PHARMACEUTICALS LLC: NET REVENUE, 2019-2021 ($MILLION)
  • FIGURE 73. AMNEAL PHARMACEUTICALS LLC: REVENUE SHARE BY SEGMENT, 2021 (%)
目次
Product Code: A12673

The oral antiviral market size valued for $35,213.48 million in 2021 and is estimated to reach $43,394.00 million by 2031, exhibiting a CAGR of 2.1% from 2022 to 2031.  

Antiviral drugs are a class of medicines particularly used for the treatment of viral infections. Specific antiviral drugs are used for treating specific type of viruses. Oral antiviral agents are medications that are taken by mouth to treat viral infections. In addition, antiviral drugs, unlike the most antibiotics, do not destroy their target pathogens; rather inhibit their development. Further, these drugs work by interfering with various stages of the viral life cycle, such as replication or assembly, reduce the severity and duration of symptoms, as well as reduce the spread of the virus to others. Moreover, many oral antiviral drugs are approved and available for treating viral infections such as baloxavir marboxil & zanamivir for influenza, ledipasvir-sofosbuvir for hepatitis and darunavir & lamivudine for human immunodeficiency virus (HIV). 

The driving factors for oral antiviral market are rise in prevalence of viral infections such as influenza, human immunodeficiency virus (HIV) and hepatitis. For instance, according to the report of the Centers for Disease Control and Prevention (CDC) 2022, 9 million cases of influenza were reported, with 4 million medical visits and 10,000 hospitalizations. Thus, a rise in prevalence of influenza is expected to drive the growth of the market. In addition, rise in prevalence of hepatitis and herpes cases across the globe is anticipated to drive the growth of market. Further, increase in number of pipeline medications for treating viral infections that is anticipated to receive regulatory approval in the upcoming years; thus, driving the growth of market.  

Furthermore, rise in initiatives by non-government & government organizations to increase awareness about the viral diseases and available oral treatment among the patients through different programs and campaigns is predicted to boost the growth of the market. In addition, rise in adoption of advanced technologies to diagnose viral diseases and awareness about the importance of early diagnosis of viral infections such as hepatitis and human immunodeficiency virus (HIV) is anticipated to boost the market growth. Furthermore, many key players have adopted key strategies such as collaboration, agreement, or alliance to increase their market presence in the global oral antiviral market, which is expected to drive the growth of the market.    

However, factors such as the high cost of oral antivirals might restrain the growth of oral antiviral market. In addition, availability of vaccines for viral diseases such as influenza, hepatitis, human papillomavirus (HPV) and herpes is expected to hamper the growth of market. Moreover, rise in demand of novel therapeutics for treating viral infections and rise in regulatory approvals for antiviral drugs is expected to offer lucrative opportunities to key players of market. 

The global oral antiviral market is segmented into indication, drug class, distribution channel, and region. On the basis of indication, the market is categorized into hepatitis, human immunodeficiency virus (HIV), influenza and others. On the basis of drug class, the market is categorized into protease inhibitors, reverse transcriptase inhibitors and others. On the basis of distribution channel, the market is segregated into hospital pharmacies, drug stores and retail pharmacies and online providers. Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major Key players that operate in the global oral antiviral market are: AbbVie Inc., Amneal Pharmaceuticals LLC, Bristol-Myers Squibb Company, F. Hoffman-La Roche Ltd, GlaxoSmithKline plc, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the oral antiviral market analysis from 2021 to 2031 to identify the prevailing oral antiviral market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the oral antiviral market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global oral antiviral market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Indication

  • Hepatitis
  • Human Immunodeficiency Virus (HIV)
  • Influenza
  • Others

By Drug class

  • Protease inhibitors
  • Reverse transcriptase inhibitors
  • Others

By Distribution channel

  • Hospital pharmacies
  • Drug store and retail pharmacies
  • Online providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players

  • F. Hoffman-La Roche Ltd
  • Merck & Co., Inc.
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.
  • Amneal Pharmaceuticals LLC
  • Viatris Inc.
  • AbbVie Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. Bargaining power of suppliers
    • 3.3.2. Bargaining power of buyers
    • 3.3.3. Threat of substitutes
    • 3.3.4. Threat of new entrants
    • 3.3.5. Intensity of rivalry
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Increasing prevalence of viral infection
      • 3.4.1.2. Increasing government initiatives regarding viral infections
      • 3.4.1.3. Rise in approval of antiviral drugs
    • 3.4.2. Restraints
      • 3.4.2.1. Stringent regulatory requirements for the approval and commercialization of HIV drugs
    • 3.4.3. Opportunities
      • 3.4.3.1. Growth opportunities in emerging markets
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: ORAL ANTIVIRAL MARKET, BY INDICATION

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Hepatitis
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Human Immunodeficiency Virus (HIV)
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Influenza
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country
  • 4.5. Others
    • 4.5.1. Key market trends, growth factors and opportunities
    • 4.5.2. Market size and forecast, by region
    • 4.5.3. Market share analysis by country

CHAPTER 5: ORAL ANTIVIRAL MARKET, BY DRUG CLASS

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Protease inhibitors
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Reverse transcriptase inhibitors
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: ORAL ANTIVIRAL MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug store and retail pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: ORAL ANTIVIRAL MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key trends and opportunities
    • 7.2.2. Market size and forecast, by Indication
    • 7.2.3. Market size and forecast, by Drug class
    • 7.2.4. Market size and forecast, by Distribution channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Key market trends, growth factors and opportunities
      • 7.2.5.1.2. Market size and forecast, by Indication
      • 7.2.5.1.3. Market size and forecast, by Drug class
      • 7.2.5.1.4. Market size and forecast, by Distribution channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Key market trends, growth factors and opportunities
      • 7.2.5.2.2. Market size and forecast, by Indication
      • 7.2.5.2.3. Market size and forecast, by Drug class
      • 7.2.5.2.4. Market size and forecast, by Distribution channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Key market trends, growth factors and opportunities
      • 7.2.5.3.2. Market size and forecast, by Indication
      • 7.2.5.3.3. Market size and forecast, by Drug class
      • 7.2.5.3.4. Market size and forecast, by Distribution channel
  • 7.3. Europe
    • 7.3.1. Key trends and opportunities
    • 7.3.2. Market size and forecast, by Indication
    • 7.3.3. Market size and forecast, by Drug class
    • 7.3.4. Market size and forecast, by Distribution channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Key market trends, growth factors and opportunities
      • 7.3.5.1.2. Market size and forecast, by Indication
      • 7.3.5.1.3. Market size and forecast, by Drug class
      • 7.3.5.1.4. Market size and forecast, by Distribution channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Key market trends, growth factors and opportunities
      • 7.3.5.2.2. Market size and forecast, by Indication
      • 7.3.5.2.3. Market size and forecast, by Drug class
      • 7.3.5.2.4. Market size and forecast, by Distribution channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Key market trends, growth factors and opportunities
      • 7.3.5.3.2. Market size and forecast, by Indication
      • 7.3.5.3.3. Market size and forecast, by Drug class
      • 7.3.5.3.4. Market size and forecast, by Distribution channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Key market trends, growth factors and opportunities
      • 7.3.5.4.2. Market size and forecast, by Indication
      • 7.3.5.4.3. Market size and forecast, by Drug class
      • 7.3.5.4.4. Market size and forecast, by Distribution channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Key market trends, growth factors and opportunities
      • 7.3.5.5.2. Market size and forecast, by Indication
      • 7.3.5.5.3. Market size and forecast, by Drug class
      • 7.3.5.5.4. Market size and forecast, by Distribution channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Key market trends, growth factors and opportunities
      • 7.3.5.6.2. Market size and forecast, by Indication
      • 7.3.5.6.3. Market size and forecast, by Drug class
      • 7.3.5.6.4. Market size and forecast, by Distribution channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key trends and opportunities
    • 7.4.2. Market size and forecast, by Indication
    • 7.4.3. Market size and forecast, by Drug class
    • 7.4.4. Market size and forecast, by Distribution channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Key market trends, growth factors and opportunities
      • 7.4.5.1.2. Market size and forecast, by Indication
      • 7.4.5.1.3. Market size and forecast, by Drug class
      • 7.4.5.1.4. Market size and forecast, by Distribution channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Key market trends, growth factors and opportunities
      • 7.4.5.2.2. Market size and forecast, by Indication
      • 7.4.5.2.3. Market size and forecast, by Drug class
      • 7.4.5.2.4. Market size and forecast, by Distribution channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Key market trends, growth factors and opportunities
      • 7.4.5.3.2. Market size and forecast, by Indication
      • 7.4.5.3.3. Market size and forecast, by Drug class
      • 7.4.5.3.4. Market size and forecast, by Distribution channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Key market trends, growth factors and opportunities
      • 7.4.5.4.2. Market size and forecast, by Indication
      • 7.4.5.4.3. Market size and forecast, by Drug class
      • 7.4.5.4.4. Market size and forecast, by Distribution channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Key market trends, growth factors and opportunities
      • 7.4.5.5.2. Market size and forecast, by Indication
      • 7.4.5.5.3. Market size and forecast, by Drug class
      • 7.4.5.5.4. Market size and forecast, by Distribution channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Key market trends, growth factors and opportunities
      • 7.4.5.6.2. Market size and forecast, by Indication
      • 7.4.5.6.3. Market size and forecast, by Drug class
      • 7.4.5.6.4. Market size and forecast, by Distribution channel
  • 7.5. LAMEA
    • 7.5.1. Key trends and opportunities
    • 7.5.2. Market size and forecast, by Indication
    • 7.5.3. Market size and forecast, by Drug class
    • 7.5.4. Market size and forecast, by Distribution channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Key market trends, growth factors and opportunities
      • 7.5.5.1.2. Market size and forecast, by Indication
      • 7.5.5.1.3. Market size and forecast, by Drug class
      • 7.5.5.1.4. Market size and forecast, by Distribution channel
      • 7.5.5.2. Saudi Arabia
      • 7.5.5.2.1. Key market trends, growth factors and opportunities
      • 7.5.5.2.2. Market size and forecast, by Indication
      • 7.5.5.2.3. Market size and forecast, by Drug class
      • 7.5.5.2.4. Market size and forecast, by Distribution channel
      • 7.5.5.3. South Africa
      • 7.5.5.3.1. Key market trends, growth factors and opportunities
      • 7.5.5.3.2. Market size and forecast, by Indication
      • 7.5.5.3.3. Market size and forecast, by Drug class
      • 7.5.5.3.4. Market size and forecast, by Distribution channel
      • 7.5.5.4. Rest of LAMEA
      • 7.5.5.4.1. Key market trends, growth factors and opportunities
      • 7.5.5.4.2. Market size and forecast, by Indication
      • 7.5.5.4.3. Market size and forecast, by Drug class
      • 7.5.5.4.4. Market size and forecast, by Distribution channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top player positioning, 2021

CHAPTER 9: COMPANY PROFILES

  • 9.1. Gilead Sciences, Inc.
    • 9.1.1. Company overview
    • 9.1.2. Key Executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. F. Hoffmann-La Roche Ltd.
    • 9.2.1. Company overview
    • 9.2.2. Key Executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. Merck & Co., Inc.
    • 9.3.1. Company overview
    • 9.3.2. Key Executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
  • 9.4. AbbVie Inc.
    • 9.4.1. Company overview
    • 9.4.2. Key Executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. GlaxoSmithKline plc
    • 9.5.1. Company overview
    • 9.5.2. Key Executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Bristol-Myers Squibb Company
    • 9.6.1. Company overview
    • 9.6.2. Key Executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
  • 9.7. Johnson & Johnson
    • 9.7.1. Company overview
    • 9.7.2. Key Executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
  • 9.8. Teva Pharmaceutical Industries Ltd.
    • 9.8.1. Company overview
    • 9.8.2. Key Executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
  • 9.9. Viatris Inc.
    • 9.9.1. Company overview
    • 9.9.2. Key Executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
  • 9.10. Amneal Pharmaceuticals LLC
    • 9.10.1. Company overview
    • 9.10.2. Key Executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance